Tesaro Inc (TSRO) 62.25 $TSRO
TESARO Announces Participation at Three Investor Conferences
GlobeNewswire - Wed Apr 22, 7:15AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three investor conferences during the month of May, including:
TSRO: 62.25 (-1.08)
TESARO to Announce First-Quarter Financial Results on April 30, 2015
GlobeNewswire - Thu Apr 16, 7:05AM CDT
TESARO, Inc. (Nasdaq:TSRO) will announce its first-quarter 2015 financial results on Thursday, April 30, 2015, after the close of the U.S. financial markets. TESARO's senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on April 30, 2015 to provide a business and pipeline update and discuss the Company's results in greater detail.
TSRO: 62.25 (-1.08)
TESARO Announces Upcoming Immuno-Oncology Presentations
GlobeNewswire - Tue Apr 14, 7:01AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced two upcoming presentations related to its immuno-oncology portfolio.
TSRO: 62.25 (-1.08)
TESARO Announces Nomination of Garry A. Nicholson for Election to Board of Directors
GlobeNewswire - Thu Apr 09, 7:15AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the nomination of Garry A. Nicholson for election to the Company's Board of Directors. He will stand for election as an independent director at TESARO's 2015 annual meeting of stockholders, which is scheduled for May 14, 2015.
TSRO: 62.25 (-1.08)
TESARO Appoints Joseph Farmer, as Senior Vice President, General Counsel and Secretary
GlobeNewswire - Tue Mar 31, 6:01AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Joseph L. Farmer as Senior Vice President, General Counsel and Secretary. Mr. Farmer most recently served as Vice President, Chief Corporate Counsel and Assistant Secretary of Cubist Pharmaceuticals, Inc., where he led the corporate legal operations of a rapidly growing public company with multiple commercial and development stage products.
CBSTZ: 0.06 (unch), TSRO: 62.25 (-1.08)
TESARO concludes sale of 3.756m common stock in public offering, including underwriters' over-allotment option
M2 - Tue Mar 10, 5:35AM CDT
Biopharmaceutical company TESARO (Nasdaq:TSRO) reported on Monday the sale of 3,755,000 common stock at an offering price of USD51.00 per share under its public offering.
TSRO: 62.25 (-1.08)
Tesaro raises almost $180M in equity offering
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 3:16PM CDT
TSRO: 62.25 (-1.08)
TESARO Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option by Underwriters
GlobeNewswire - Mon Mar 09, 3:01PM CDT
TESARO, Inc. (Nasdaq:TSRO) today announced the closing of its previously announced underwritten public offering of common stock. TESARO sold 3,755,000 shares of common stock at an offering price to the public of $51.00 per share, which included 355,000 shares of common stock sold pursuant to the partial exercise of the underwriters' over-allotment option to purchase up to 510,000 additional shares. TESARO estimates that the net proceeds from the offering will be approximately $179.7 million, after deducting the underwriting discount and other offering expenses payable by TESARO and subject to any future exercise of the remaining portion of the underwriters' over-allotment option. Citigroup, Leerink Partners and Deutsche Bank Securities acted as joint book-running managers for the offering, with BMO Capital Markets, Robert W. Baird & Co. Incorporated and Mizuho Securities acting as co-managers for the offering.
TSRO: 62.25 (-1.08), DB: 33.95 (+0.61)
Heron Therapeutics adds to pain med trial-stoked up move
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 3:35PM CST
INSY: 62.10 (+0.76), TSRO: 62.25 (-1.08), HRTX: 14.17 (-0.02), OPK: 14.60 (+0.17)
3 Biotech Stocks That Are Soaring Higher
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 03, 9:58AM CST
Three biotech stocks were among the market's best-performing companies last week. Two of them are highly speculative, clinical-stage biotech stocks that surged on optimism about drugs in their pipelines. The third is commercial stage big-cap biotech...
PCYC: 256.98 (-0.77), TSRO: 62.25 (-1.08), PTCT: 70.98 (unch)
Tesaro initiates equity offering
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 4:15PM CST
TSRO: 62.25 (-1.08)
TESARO Announces Proposed Public Offering of Common Stock
GlobeNewswire - Mon Mar 02, 3:05PM CST
TESARO, Inc. (Nasdaq:TSRO) announced today that it has commenced an underwritten public offering of $150 million of its common stock. In connection with this offering, TESARO plans to grant the underwriters an option to purchase up to an additional $22.5 million of its common stock to cover over-allotments. Citigroup, Leerink Partners and Deutsche Bank Securities are acting as joint book-running managers for the offering, with BMO Capital Markets, Robert W. Baird & Co. Incorporated and Mizuho acting as co-managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
TSRO: 62.25 (-1.08), DB: 33.95 (+0.61)
Nasdaq stocks posting largest percentage increases
AP - Tue Feb 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
FSLR: 63.88 (+0.77), TSRO: 62.25 (-1.08), STAA: 9.01 (unch), AFMD: 7.94 (+0.11), CERU: 5.99 (-0.20), RLYP: 35.39 (-0.54), TSEM: 17.36 (-0.07), PTCT: 70.98 (unch), DEPO: 27.14 (+0.65), DGLY: 13.13 (+0.08), GTLS: 40.68 (+0.51)
TESARO (TSRO) is in Overbought Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 24, 6:23AM CST
TESARO (TSRO) is in Overbought Territory: What’s Next?
TSRO: 62.25 (-1.08)
Tesaro Q4 results
Seeking Alpha - at Seeking Alpha - Fri Feb 20, 8:26AM CST
TSRO: 62.25 (-1.08)
TESARO's (TSRO) CEO Lonnie Moulder on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 19, 6:46PM CST
TSRO: 62.25 (-1.08)
Tesaro misses by $0.30
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 3:05PM CST
TSRO: 62.25 (-1.08)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Feb 18, 4:35PM CST
ANET: 66.27 (+0.40), FNGN: 42.51 (+0.44), TSRO: 62.25 (-1.08), AUQ: 3.48 (-0.16), ED: 61.64 (+0.17), PSA: 192.81 (+1.17), MRC: 13.99 (-0.12), FR: 20.19 (-0.10), TEP: 49.61 (-0.25), HY: 72.99 (-0.55), SAAS: 10.39 (+0.05), EGO: 4.80 (-0.07), TRUE: 15.72 (-0.26), SPN: 23.84 (+0.41), BLDR: 13.00 (-0.09), ROVI: 19.46 (+0.10), FTR: 7.10 (+0.04), ACTG: 9.83 (-0.08), TRMR: 3.01 (+0.42), CYH: 54.41 (+0.55), SSRI: 5.39 (-0.22), NEM: 22.77 (-0.74), FUEL: 8.97 (+0.01), IPCM: 52.02 (-0.06), AHS: 24.03 (-0.29), EXR: 66.97 (+0.09), INAP: 10.70 (+0.08), SEM: 15.29 (+0.27), BRCD: 11.99 (+0.09), FRGI: 59.39 (-0.22), XNPT: 7.42 (+0.12), SPNC: 34.65 (-0.07), WRE: 26.00 (-0.35), EQIX: 244.78 (+1.00), MRVL: 14.76 (-0.18), GEN: 7.28 (+0.08), MHK: 182.02 (+2.39), BEAT: 8.82 (-0.13), NDLS: 19.73 (+0.31), FPO: 11.17 (-0.08), WIRE: 40.01 (-0.02), JWN: 78.01 (+0.40), BRKR: 19.38 (-0.35), BAS: 7.88 (+0.07), INTU: 100.16 (+2.92)
Investing In Precision Oncology: Targeting NTRK Genomic Alterations
Bay Area Biotech - at Seeking Alpha - Wed Feb 18, 10:44AM CST
LOXO: 13.21 (-0.01), TSRO: 62.25 (-1.08), RXDX: 9.92 (-0.30), PFE: 34.93 (+0.04), MRTX: 27.86 (-0.19), NVS: 103.45 (-0.62), ARRY: 7.25 (-0.10)
TESARO Announces Participation at Three Investor Conferences
GlobeNewswire - Wed Apr 22, 7:15AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three investor conferences during the month of May, including:
TSRO: 62.25 (-1.08)
TESARO to Announce First-Quarter Financial Results on April 30, 2015
GlobeNewswire - Thu Apr 16, 7:05AM CDT
TESARO, Inc. (Nasdaq:TSRO) will announce its first-quarter 2015 financial results on Thursday, April 30, 2015, after the close of the U.S. financial markets. TESARO's senior management team will host a conference call and live audio webcast at 4:15 p.m. ET on April 30, 2015 to provide a business and pipeline update and discuss the Company's results in greater detail.
TSRO: 62.25 (-1.08)
TESARO Announces Upcoming Immuno-Oncology Presentations
GlobeNewswire - Tue Apr 14, 7:01AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced two upcoming presentations related to its immuno-oncology portfolio.
TSRO: 62.25 (-1.08)
TESARO Announces Nomination of Garry A. Nicholson for Election to Board of Directors
GlobeNewswire - Thu Apr 09, 7:15AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the nomination of Garry A. Nicholson for election to the Company's Board of Directors. He will stand for election as an independent director at TESARO's 2015 annual meeting of stockholders, which is scheduled for May 14, 2015.
TSRO: 62.25 (-1.08)
TESARO Appoints Joseph Farmer, as Senior Vice President, General Counsel and Secretary
GlobeNewswire - Tue Mar 31, 6:01AM CDT
TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Joseph L. Farmer as Senior Vice President, General Counsel and Secretary. Mr. Farmer most recently served as Vice President, Chief Corporate Counsel and Assistant Secretary of Cubist Pharmaceuticals, Inc., where he led the corporate legal operations of a rapidly growing public company with multiple commercial and development stage products.
CBSTZ: 0.06 (unch), TSRO: 62.25 (-1.08)
TESARO concludes sale of 3.756m common stock in public offering, including underwriters' over-allotment option
M2 - Tue Mar 10, 5:35AM CDT
Biopharmaceutical company TESARO (Nasdaq:TSRO) reported on Monday the sale of 3,755,000 common stock at an offering price of USD51.00 per share under its public offering.
TSRO: 62.25 (-1.08)
Tesaro raises almost $180M in equity offering
Seeking Alpha - at Seeking Alpha - Mon Mar 09, 3:16PM CDT
TSRO: 62.25 (-1.08)
TESARO Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option by Underwriters
GlobeNewswire - Mon Mar 09, 3:01PM CDT
TESARO, Inc. (Nasdaq:TSRO) today announced the closing of its previously announced underwritten public offering of common stock. TESARO sold 3,755,000 shares of common stock at an offering price to the public of $51.00 per share, which included 355,000 shares of common stock sold pursuant to the partial exercise of the underwriters' over-allotment option to purchase up to 510,000 additional shares. TESARO estimates that the net proceeds from the offering will be approximately $179.7 million, after deducting the underwriting discount and other offering expenses payable by TESARO and subject to any future exercise of the remaining portion of the underwriters' over-allotment option. Citigroup, Leerink Partners and Deutsche Bank Securities acted as joint book-running managers for the offering, with BMO Capital Markets, Robert W. Baird & Co. Incorporated and Mizuho Securities acting as co-managers for the offering.
TSRO: 62.25 (-1.08), DB: 33.95 (+0.61)
Heron Therapeutics adds to pain med trial-stoked up move
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 3:35PM CST
INSY: 62.10 (+0.76), TSRO: 62.25 (-1.08), HRTX: 14.17 (-0.02), OPK: 14.60 (+0.17)
3 Biotech Stocks That Are Soaring Higher
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 03, 9:58AM CST
Three biotech stocks were among the market's best-performing companies last week. Two of them are highly speculative, clinical-stage biotech stocks that surged on optimism about drugs in their pipelines. The third is commercial stage big-cap biotech...
PCYC: 256.98 (-0.77), TSRO: 62.25 (-1.08), PTCT: 70.98 (unch)
Tesaro initiates equity offering
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 4:15PM CST
TSRO: 62.25 (-1.08)
TESARO Announces Proposed Public Offering of Common Stock
GlobeNewswire - Mon Mar 02, 3:05PM CST
TESARO, Inc. (Nasdaq:TSRO) announced today that it has commenced an underwritten public offering of $150 million of its common stock. In connection with this offering, TESARO plans to grant the underwriters an option to purchase up to an additional $22.5 million of its common stock to cover over-allotments. Citigroup, Leerink Partners and Deutsche Bank Securities are acting as joint book-running managers for the offering, with BMO Capital Markets, Robert W. Baird & Co. Incorporated and Mizuho acting as co-managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
TSRO: 62.25 (-1.08), DB: 33.95 (+0.61)
Nasdaq stocks posting largest percentage increases
AP - Tue Feb 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
FSLR: 63.88 (+0.77), TSRO: 62.25 (-1.08), STAA: 9.01 (unch), AFMD: 7.94 (+0.11), CERU: 5.99 (-0.20), RLYP: 35.39 (-0.54), TSEM: 17.36 (-0.07), PTCT: 70.98 (unch), DEPO: 27.14 (+0.65), DGLY: 13.13 (+0.08), GTLS: 40.68 (+0.51)
TESARO (TSRO) is in Overbought Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 24, 6:23AM CST
TESARO (TSRO) is in Overbought Territory: What’s Next?
TSRO: 62.25 (-1.08)
Tesaro Q4 results
Seeking Alpha - at Seeking Alpha - Fri Feb 20, 8:26AM CST
TSRO: 62.25 (-1.08)
TESARO's (TSRO) CEO Lonnie Moulder on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 19, 6:46PM CST
TSRO: 62.25 (-1.08)
Tesaro misses by $0.30
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 3:05PM CST
TSRO: 62.25 (-1.08)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Feb 18, 4:35PM CST
ANET: 66.27 (+0.40), FNGN: 42.51 (+0.44), TSRO: 62.25 (-1.08), AUQ: 3.48 (-0.16), ED: 61.64 (+0.17), PSA: 192.81 (+1.17), MRC: 13.99 (-0.12), FR: 20.19 (-0.10), TEP: 49.61 (-0.25), HY: 72.99 (-0.55), SAAS: 10.39 (+0.05), EGO: 4.80 (-0.07), TRUE: 15.72 (-0.26), SPN: 23.84 (+0.41), BLDR: 13.00 (-0.09), ROVI: 19.46 (+0.10), FTR: 7.10 (+0.04), ACTG: 9.83 (-0.08), TRMR: 3.01 (+0.42), CYH: 54.41 (+0.55), SSRI: 5.39 (-0.22), NEM: 22.77 (-0.74), FUEL: 8.97 (+0.01), IPCM: 52.02 (-0.06), AHS: 24.03 (-0.29), EXR: 66.97 (+0.09), INAP: 10.70 (+0.08), SEM: 15.29 (+0.27), BRCD: 11.99 (+0.09), FRGI: 59.39 (-0.22), XNPT: 7.42 (+0.12), SPNC: 34.65 (-0.07), WRE: 26.00 (-0.35), EQIX: 244.78 (+1.00), MRVL: 14.76 (-0.18), GEN: 7.28 (+0.08), MHK: 182.02 (+2.39), BEAT: 8.82 (-0.13), NDLS: 19.73 (+0.31), FPO: 11.17 (-0.08), WIRE: 40.01 (-0.02), JWN: 78.01 (+0.40), BRKR: 19.38 (-0.35), BAS: 7.88 (+0.07), INTU: 100.16 (+2.92)
Investing In Precision Oncology: Targeting NTRK Genomic Alterations
Bay Area Biotech - at Seeking Alpha - Wed Feb 18, 10:44AM CST
LOXO: 13.21 (-0.01), TSRO: 62.25 (-1.08), RXDX: 9.92 (-0.30), PFE: 34.93 (+0.04), MRTX: 27.86 (-0.19), NVS: 103.45 (-0.62), ARRY: 7.25 (-0.10)
